Article

Tau Disaggregation by a CNS-Permeable Small Molecule Reduces Fibril and Oligomer Burden and Preserves Proteostasis and Behavior

2026-06-12

Abstract excerpt

Pathological tau aggregates drive neuronal dysfunction in Alzheimer’s disease (AD) and related tauopathies, yet no approved therapy eliminates existing tau neurofibrillary tangles. Here, we report the development of a coumarin-based small-molecule series that disaggregates tau fibrils and oligomers through a stacking-driven co-assembly mechanism. Structure-activity relationships identified PT-13 as a lead compound...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c0f01503-afd8-5afe-964c-d5e6a5545871
DOI: 10.64898/2026.06.09.731185

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Tau Disaggregation by a CNS-Permeable Small Molecule Reduces Fibril and Oligomer Burden and Preserves Proteostasis and BehaviorDOI 10.64898/2026.06.09.731185Read

[Tauopathies : From molecule to therapy].Semantic proximity Read

Ensemble-based design of tau to inhibit aggregation while preserving biological activitySemantic proximity Read

Dual Inhibitors Targeting G9a and GSK-3β: Translational Perspectives on Alzheimer’s Disease TreatmentSemantic proximity Read

Repurposed COMT Inhibitors Tolcapone and Entacapone Selectively Suppress Aggregation and Seeding of P301 Mutant TAU in Human Neuronal ModelsSemantic proximity Read

Design of Tau Aggregation Inhibitors Using Iterative Machine Learning and a Polymorph-Specific Brain-Seeded Fibril Amplification AssaySemantic proximity Read

PE859, a Novel Tau Aggregation Inhibitor, Reduces Aggregated Tau and Prevents Onset and Progression of Neural Dysfunction In VivoSemantic proximity Read

Structural and functional insights into the selective inhibition of mutant tau aggregation by purpurin and oleocanthal in frontotemporal dementia.Semantic proximity Read

Mechanistic studies unravel the complexity inherent in tau aggregation leading to Alzheimer's disease and the tauopathies.Semantic proximity Read

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In VivoSemantic proximity Read

Structure-based inhibitors halt prion-like seeding by Alzheimer’s disease–and tauopathy–derived brain tissue samplesSemantic proximity Read

Disease associated mutations in tau encode for changes in aggregate structure conformationSemantic proximity Read

Tau seeding and spreading in vivo is supported by both AD-derived fibrillar and oligomeric tauSemantic proximity Read